nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2A6—prostate cancer	0.171	0.397	CbGaD
Arformoterol—ADRB2—prostate cancer	0.139	0.324	CbGaD
Arformoterol—CYP2C19—prostate cancer	0.12	0.279	CbGaD
Arformoterol—CYP2C19—Bicalutamide—prostate cancer	0.0401	0.128	CbGbCtD
Arformoterol—CYP2C19—Nilutamide—prostate cancer	0.0401	0.128	CbGbCtD
Arformoterol—CYP2C9—Nilutamide—prostate cancer	0.0334	0.107	CbGbCtD
Arformoterol—CYP2C9—Bicalutamide—prostate cancer	0.0334	0.107	CbGbCtD
Arformoterol—CYP2C19—Flutamide—prostate cancer	0.0332	0.106	CbGbCtD
Arformoterol—CYP2D6—Bicalutamide—prostate cancer	0.0305	0.0975	CbGbCtD
Arformoterol—CYP2D6—Abiraterone—prostate cancer	0.0253	0.0808	CbGbCtD
Arformoterol—CYP2C9—Estrone—prostate cancer	0.02	0.0639	CbGbCtD
Arformoterol—CYP2C9—Capecitabine—prostate cancer	0.0151	0.0484	CbGbCtD
Arformoterol—CYP2C19—Estradiol—prostate cancer	0.0138	0.0441	CbGbCtD
Arformoterol—CYP2C19—Prednisone—prostate cancer	0.0119	0.0379	CbGbCtD
Arformoterol—CYP2C9—Estradiol—prostate cancer	0.0115	0.0367	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—prostate cancer	0.00467	0.0149	CbGbCtD
Arformoterol—Dobutamine—COMT—prostate cancer	0.000534	0.164	CrCbGaD
Arformoterol—Formoterol—CYP2A6—prostate cancer	0.000369	0.114	CrCbGaD
Arformoterol—Ritodrine—ADRB2—prostate cancer	0.000332	0.102	CrCbGaD
Arformoterol—Fenoterol—ADRB2—prostate cancer	0.000332	0.102	CrCbGaD
Arformoterol—Arbutamine—ADRB2—prostate cancer	0.000311	0.0957	CrCbGaD
Arformoterol—Formoterol—ADRB2—prostate cancer	0.000302	0.0929	CrCbGaD
Arformoterol—CYP2C19—urine—prostate cancer	0.000295	0.246	CbGeAlD
Arformoterol—Dobutamine—ADRB2—prostate cancer	0.000286	0.0881	CrCbGaD
Arformoterol—Formoterol—CYP2C19—prostate cancer	0.00026	0.08	CrCbGaD
Arformoterol—CYP2C9—urine—prostate cancer	0.000229	0.19	CbGeAlD
Arformoterol—Labetalol—ADRB2—prostate cancer	0.00022	0.0679	CrCbGaD
Arformoterol—CYP2D6—urine—prostate cancer	0.000172	0.143	CbGeAlD
Arformoterol—CYP2A6—prostate gland—prostate cancer	0.000165	0.137	CbGeAlD
Arformoterol—Isoprenaline—ADRB2—prostate cancer	0.000162	0.05	CrCbGaD
Arformoterol—CYP2A6—seminal vesicle—prostate cancer	0.000139	0.116	CbGeAlD
Arformoterol—Isoprenaline—CYP1A1—prostate cancer	0.000139	0.0428	CrCbGaD
Arformoterol—ADRB1—prostate gland—prostate cancer	0.000132	0.11	CbGeAlD
Arformoterol—CYP2D6—renal system—prostate cancer	4.21e-05	0.035	CbGeAlD
Arformoterol—Infection—Docetaxel—prostate cancer	4.09e-05	0.000237	CcSEcCtD
Arformoterol—Sinusitis—Epirubicin—prostate cancer	4.09e-05	0.000237	CcSEcCtD
Arformoterol—Feeling abnormal—Etoposide—prostate cancer	4.09e-05	0.000236	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—prostate cancer	4.08e-05	0.000236	CcSEcCtD
Arformoterol—Diarrhoea—Mitoxantrone—prostate cancer	4.08e-05	0.000236	CcSEcCtD
Arformoterol—Dry mouth—Capecitabine—prostate cancer	4.07e-05	0.000235	CcSEcCtD
Arformoterol—Vomiting—Estradiol—prostate cancer	4.07e-05	0.000235	CcSEcCtD
Arformoterol—Gastrointestinal pain—Etoposide—prostate cancer	4.05e-05	0.000235	CcSEcCtD
Arformoterol—Nervous system disorder—Docetaxel—prostate cancer	4.04e-05	0.000234	CcSEcCtD
Arformoterol—Ill-defined disorder—Prednisone—prostate cancer	4.04e-05	0.000234	CcSEcCtD
Arformoterol—Rash—Estradiol—prostate cancer	4.03e-05	0.000233	CcSEcCtD
Arformoterol—Dermatitis—Estradiol—prostate cancer	4.03e-05	0.000233	CcSEcCtD
Arformoterol—Tachycardia—Docetaxel—prostate cancer	4.02e-05	0.000233	CcSEcCtD
Arformoterol—Headache—Estradiol—prostate cancer	4.01e-05	0.000232	CcSEcCtD
Arformoterol—Skin disorder—Docetaxel—prostate cancer	4e-05	0.000232	CcSEcCtD
Arformoterol—Agitation—Prednisone—prostate cancer	4e-05	0.000231	CcSEcCtD
Arformoterol—Oedema—Capecitabine—prostate cancer	3.99e-05	0.000231	CcSEcCtD
Arformoterol—Angioedema—Prednisone—prostate cancer	3.98e-05	0.00023	CcSEcCtD
Arformoterol—Infection—Capecitabine—prostate cancer	3.96e-05	0.000229	CcSEcCtD
Arformoterol—Urticaria—Etoposide—prostate cancer	3.94e-05	0.000228	CcSEcCtD
Arformoterol—Malaise—Prednisone—prostate cancer	3.93e-05	0.000227	CcSEcCtD
Arformoterol—Rhinitis—Epirubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Arformoterol—Body temperature increased—Etoposide—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Arformoterol—Abdominal pain—Etoposide—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—prostate cancer	3.92e-05	0.000227	CcSEcCtD
Arformoterol—Nervous system disorder—Capecitabine—prostate cancer	3.91e-05	0.000226	CcSEcCtD
Arformoterol—Tachycardia—Capecitabine—prostate cancer	3.89e-05	0.000225	CcSEcCtD
Arformoterol—Pharyngitis—Epirubicin—prostate cancer	3.88e-05	0.000225	CcSEcCtD
Arformoterol—Skin disorder—Capecitabine—prostate cancer	3.87e-05	0.000224	CcSEcCtD
Arformoterol—Urinary tract disorder—Epirubicin—prostate cancer	3.86e-05	0.000223	CcSEcCtD
Arformoterol—Oedema peripheral—Epirubicin—prostate cancer	3.85e-05	0.000223	CcSEcCtD
Arformoterol—Hypotension—Docetaxel—prostate cancer	3.85e-05	0.000223	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—prostate cancer	3.84e-05	0.000222	CcSEcCtD
Arformoterol—Connective tissue disorder—Epirubicin—prostate cancer	3.84e-05	0.000222	CcSEcCtD
Arformoterol—Urethral disorder—Epirubicin—prostate cancer	3.83e-05	0.000222	CcSEcCtD
Arformoterol—Nausea—Estradiol—prostate cancer	3.8e-05	0.00022	CcSEcCtD
Arformoterol—Vomiting—Mitoxantrone—prostate cancer	3.79e-05	0.000219	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—prostate cancer	3.78e-05	0.000219	CcSEcCtD
Arformoterol—Visual impairment—Epirubicin—prostate cancer	3.77e-05	0.000218	CcSEcCtD
Arformoterol—Hypertension—Prednisone—prostate cancer	3.76e-05	0.000217	CcSEcCtD
Arformoterol—Rash—Mitoxantrone—prostate cancer	3.76e-05	0.000217	CcSEcCtD
Arformoterol—Dermatitis—Mitoxantrone—prostate cancer	3.75e-05	0.000217	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.75e-05	0.000217	CcSEcCtD
Arformoterol—Headache—Mitoxantrone—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Arformoterol—Hypotension—Capecitabine—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Arformoterol—Insomnia—Docetaxel—prostate cancer	3.73e-05	0.000216	CcSEcCtD
Arformoterol—Arthralgia—Prednisone—prostate cancer	3.71e-05	0.000214	CcSEcCtD
Arformoterol—Myalgia—Prednisone—prostate cancer	3.71e-05	0.000214	CcSEcCtD
Arformoterol—Anxiety—Prednisone—prostate cancer	3.69e-05	0.000214	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	3.68e-05	0.000213	CcSEcCtD
Arformoterol—Dyspnoea—Docetaxel—prostate cancer	3.67e-05	0.000213	CcSEcCtD
Arformoterol—Somnolence—Docetaxel—prostate cancer	3.66e-05	0.000212	CcSEcCtD
Arformoterol—Discomfort—Prednisone—prostate cancer	3.66e-05	0.000212	CcSEcCtD
Arformoterol—Hypersensitivity—Etoposide—prostate cancer	3.65e-05	0.000211	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Arformoterol—Cardiac disorder—Epirubicin—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Arformoterol—Dyspepsia—Docetaxel—prostate cancer	3.63e-05	0.00021	CcSEcCtD
Arformoterol—Insomnia—Capecitabine—prostate cancer	3.61e-05	0.000209	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—prostate cancer	3.59e-05	0.000208	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—prostate cancer	3.57e-05	0.000207	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—prostate cancer	3.57e-05	0.000206	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Docetaxel—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Arformoterol—Asthenia—Etoposide—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Arformoterol—Dyspnoea—Capecitabine—prostate cancer	3.56e-05	0.000206	CcSEcCtD
Arformoterol—Oedema—Prednisone—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Arformoterol—Anaphylactic shock—Prednisone—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Arformoterol—Fatigue—Docetaxel—prostate cancer	3.55e-05	0.000206	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—prostate cancer	3.55e-05	0.000205	CcSEcCtD
Arformoterol—Nausea—Mitoxantrone—prostate cancer	3.54e-05	0.000205	CcSEcCtD
Arformoterol—Immune system disorder—Epirubicin—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Arformoterol—Infection—Prednisone—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Arformoterol—Mediastinal disorder—Epirubicin—prostate cancer	3.53e-05	0.000204	CcSEcCtD
Arformoterol—Pain—Docetaxel—prostate cancer	3.52e-05	0.000204	CcSEcCtD
Arformoterol—Constipation—Docetaxel—prostate cancer	3.52e-05	0.000204	CcSEcCtD
Arformoterol—Dyspepsia—Capecitabine—prostate cancer	3.51e-05	0.000203	CcSEcCtD
Arformoterol—Pruritus—Etoposide—prostate cancer	3.51e-05	0.000203	CcSEcCtD
Arformoterol—Arrhythmia—Epirubicin—prostate cancer	3.49e-05	0.000202	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—prostate cancer	3.49e-05	0.000202	CcSEcCtD
Arformoterol—Nervous system disorder—Prednisone—prostate cancer	3.48e-05	0.000202	CcSEcCtD
Arformoterol—Tachycardia—Prednisone—prostate cancer	3.47e-05	0.000201	CcSEcCtD
Arformoterol—Skin disorder—Prednisone—prostate cancer	3.45e-05	0.0002	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Capecitabine—prostate cancer	3.44e-05	0.000199	CcSEcCtD
Arformoterol—Fatigue—Capecitabine—prostate cancer	3.44e-05	0.000199	CcSEcCtD
Arformoterol—Mental disorder—Epirubicin—prostate cancer	3.43e-05	0.000198	CcSEcCtD
Arformoterol—Pain—Capecitabine—prostate cancer	3.41e-05	0.000197	CcSEcCtD
Arformoterol—Constipation—Capecitabine—prostate cancer	3.41e-05	0.000197	CcSEcCtD
Arformoterol—Malnutrition—Epirubicin—prostate cancer	3.4e-05	0.000197	CcSEcCtD
Arformoterol—Feeling abnormal—Docetaxel—prostate cancer	3.4e-05	0.000196	CcSEcCtD
Arformoterol—Diarrhoea—Etoposide—prostate cancer	3.39e-05	0.000196	CcSEcCtD
Arformoterol—Gastrointestinal pain—Docetaxel—prostate cancer	3.37e-05	0.000195	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—prostate cancer	3.36e-05	0.000194	CcSEcCtD
Arformoterol—Tension—Epirubicin—prostate cancer	3.34e-05	0.000193	CcSEcCtD
Arformoterol—Dysgeusia—Epirubicin—prostate cancer	3.33e-05	0.000193	CcSEcCtD
Arformoterol—Nervousness—Epirubicin—prostate cancer	3.31e-05	0.000191	CcSEcCtD
Arformoterol—Back pain—Epirubicin—prostate cancer	3.29e-05	0.000191	CcSEcCtD
Arformoterol—Feeling abnormal—Capecitabine—prostate cancer	3.29e-05	0.00019	CcSEcCtD
Arformoterol—Dizziness—Etoposide—prostate cancer	3.28e-05	0.00019	CcSEcCtD
Arformoterol—Muscle spasms—Epirubicin—prostate cancer	3.27e-05	0.000189	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—prostate cancer	3.27e-05	0.000189	CcSEcCtD
Arformoterol—Gastrointestinal pain—Capecitabine—prostate cancer	3.26e-05	0.000189	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—prostate cancer	3.26e-05	0.000189	CcSEcCtD
Arformoterol—Abdominal pain—Docetaxel—prostate cancer	3.26e-05	0.000188	CcSEcCtD
Arformoterol—Body temperature increased—Docetaxel—prostate cancer	3.26e-05	0.000188	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Prednisone—prostate cancer	3.24e-05	0.000187	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—prostate cancer	3.23e-05	0.000187	CcSEcCtD
Arformoterol—Insomnia—Prednisone—prostate cancer	3.21e-05	0.000186	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—prostate cancer	3.17e-05	0.000183	CcSEcCtD
Arformoterol—Urticaria—Capecitabine—prostate cancer	3.17e-05	0.000183	CcSEcCtD
Arformoterol—Ill-defined disorder—Epirubicin—prostate cancer	3.16e-05	0.000183	CcSEcCtD
Arformoterol—Abdominal pain—Capecitabine—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Arformoterol—Body temperature increased—Capecitabine—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Arformoterol—Vomiting—Etoposide—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—prostate cancer	3.15e-05	0.000182	CcSEcCtD
Arformoterol—Agitation—Epirubicin—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Arformoterol—Dyspepsia—Prednisone—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Arformoterol—Rash—Etoposide—prostate cancer	3.13e-05	0.000181	CcSEcCtD
Arformoterol—Dermatitis—Etoposide—prostate cancer	3.12e-05	0.000181	CcSEcCtD
Arformoterol—Headache—Etoposide—prostate cancer	3.11e-05	0.00018	CcSEcCtD
Arformoterol—Tension—Doxorubicin—prostate cancer	3.09e-05	0.000179	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—prostate cancer	3.09e-05	0.000179	CcSEcCtD
Arformoterol—Malaise—Epirubicin—prostate cancer	3.07e-05	0.000178	CcSEcCtD
Arformoterol—Fatigue—Prednisone—prostate cancer	3.06e-05	0.000177	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—prostate cancer	3.06e-05	0.000177	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—prostate cancer	3.05e-05	0.000176	CcSEcCtD
Arformoterol—Constipation—Prednisone—prostate cancer	3.04e-05	0.000176	CcSEcCtD
Arformoterol—Hypersensitivity—Docetaxel—prostate cancer	3.04e-05	0.000176	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—prostate cancer	3.03e-05	0.000175	CcSEcCtD
Arformoterol—Palpitations—Epirubicin—prostate cancer	3.01e-05	0.000174	CcSEcCtD
Arformoterol—Cough—Epirubicin—prostate cancer	2.97e-05	0.000172	CcSEcCtD
Arformoterol—Asthenia—Docetaxel—prostate cancer	2.96e-05	0.000171	CcSEcCtD
Arformoterol—Nausea—Etoposide—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Arformoterol—Hypertension—Epirubicin—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Arformoterol—Hypersensitivity—Capecitabine—prostate cancer	2.94e-05	0.00017	CcSEcCtD
Arformoterol—Feeling abnormal—Prednisone—prostate cancer	2.93e-05	0.000169	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—prostate cancer	2.92e-05	0.000169	CcSEcCtD
Arformoterol—Pruritus—Docetaxel—prostate cancer	2.91e-05	0.000169	CcSEcCtD
Arformoterol—Gastrointestinal pain—Prednisone—prostate cancer	2.91e-05	0.000168	CcSEcCtD
Arformoterol—Myalgia—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Arformoterol—Arthralgia—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Arformoterol—Chest pain—Epirubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—prostate cancer	2.9e-05	0.000168	CcSEcCtD
Arformoterol—Anxiety—Epirubicin—prostate cancer	2.89e-05	0.000167	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.88e-05	0.000167	CcSEcCtD
Arformoterol—Discomfort—Epirubicin—prostate cancer	2.86e-05	0.000166	CcSEcCtD
Arformoterol—Asthenia—Capecitabine—prostate cancer	2.86e-05	0.000166	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—prostate cancer	2.84e-05	0.000164	CcSEcCtD
Arformoterol—Dry mouth—Epirubicin—prostate cancer	2.84e-05	0.000164	CcSEcCtD
Arformoterol—Urticaria—Prednisone—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Arformoterol—Pruritus—Capecitabine—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Arformoterol—Diarrhoea—Docetaxel—prostate cancer	2.82e-05	0.000163	CcSEcCtD
Arformoterol—Body temperature increased—Prednisone—prostate cancer	2.81e-05	0.000163	CcSEcCtD
Arformoterol—Abdominal pain—Prednisone—prostate cancer	2.81e-05	0.000163	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Arformoterol—Anaphylactic shock—Epirubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Arformoterol—Oedema—Epirubicin—prostate cancer	2.78e-05	0.000161	CcSEcCtD
Arformoterol—Infection—Epirubicin—prostate cancer	2.76e-05	0.00016	CcSEcCtD
Arformoterol—Cough—Doxorubicin—prostate cancer	2.75e-05	0.000159	CcSEcCtD
Arformoterol—Diarrhoea—Capecitabine—prostate cancer	2.73e-05	0.000158	CcSEcCtD
Arformoterol—Nervous system disorder—Epirubicin—prostate cancer	2.73e-05	0.000158	CcSEcCtD
Arformoterol—Dizziness—Docetaxel—prostate cancer	2.72e-05	0.000158	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—prostate cancer	2.72e-05	0.000157	CcSEcCtD
Arformoterol—CYP2D6—testis—prostate cancer	2.72e-05	0.0226	CbGeAlD
Arformoterol—Tachycardia—Epirubicin—prostate cancer	2.71e-05	0.000157	CcSEcCtD
Arformoterol—Skin disorder—Epirubicin—prostate cancer	2.7e-05	0.000156	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—prostate cancer	2.68e-05	0.000155	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—prostate cancer	2.67e-05	0.000155	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	2.66e-05	0.000154	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—prostate cancer	2.65e-05	0.000153	CcSEcCtD
Arformoterol—Dizziness—Capecitabine—prostate cancer	2.64e-05	0.000153	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—prostate cancer	2.62e-05	0.000152	CcSEcCtD
Arformoterol—Vomiting—Docetaxel—prostate cancer	2.62e-05	0.000152	CcSEcCtD
Arformoterol—Hypersensitivity—Prednisone—prostate cancer	2.62e-05	0.000151	CcSEcCtD
Arformoterol—Rash—Docetaxel—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Arformoterol—Hypotension—Epirubicin—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Arformoterol—Dermatitis—Docetaxel—prostate cancer	2.6e-05	0.00015	CcSEcCtD
Arformoterol—Headache—Docetaxel—prostate cancer	2.58e-05	0.000149	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—prostate cancer	2.57e-05	0.000149	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—prostate cancer	2.57e-05	0.000149	CcSEcCtD
Arformoterol—Infection—Doxorubicin—prostate cancer	2.55e-05	0.000148	CcSEcCtD
Arformoterol—Asthenia—Prednisone—prostate cancer	2.55e-05	0.000147	CcSEcCtD
Arformoterol—Vomiting—Capecitabine—prostate cancer	2.54e-05	0.000147	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.53e-05	0.000146	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—prostate cancer	2.52e-05	0.000146	CcSEcCtD
Arformoterol—Rash—Capecitabine—prostate cancer	2.52e-05	0.000146	CcSEcCtD
Arformoterol—Pruritus—Prednisone—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Arformoterol—Insomnia—Epirubicin—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Arformoterol—Dermatitis—Capecitabine—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—prostate cancer	2.51e-05	0.000145	CcSEcCtD
Arformoterol—Headache—Capecitabine—prostate cancer	2.5e-05	0.000145	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—prostate cancer	2.5e-05	0.000145	CcSEcCtD
Arformoterol—Dyspnoea—Epirubicin—prostate cancer	2.48e-05	0.000143	CcSEcCtD
Arformoterol—Somnolence—Epirubicin—prostate cancer	2.47e-05	0.000143	CcSEcCtD
Arformoterol—Nausea—Docetaxel—prostate cancer	2.45e-05	0.000142	CcSEcCtD
Arformoterol—Dyspepsia—Epirubicin—prostate cancer	2.45e-05	0.000142	CcSEcCtD
Arformoterol—Diarrhoea—Prednisone—prostate cancer	2.43e-05	0.000141	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Epirubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Arformoterol—Fatigue—Epirubicin—prostate cancer	2.4e-05	0.000139	CcSEcCtD
Arformoterol—Pain—Epirubicin—prostate cancer	2.38e-05	0.000137	CcSEcCtD
Arformoterol—Constipation—Epirubicin—prostate cancer	2.38e-05	0.000137	CcSEcCtD
Arformoterol—Nausea—Capecitabine—prostate cancer	2.37e-05	0.000137	CcSEcCtD
Arformoterol—Dizziness—Prednisone—prostate cancer	2.35e-05	0.000136	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.34e-05	0.000136	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—prostate cancer	2.33e-05	0.000135	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—prostate cancer	2.29e-05	0.000133	CcSEcCtD
Arformoterol—Feeling abnormal—Epirubicin—prostate cancer	2.29e-05	0.000132	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—prostate cancer	2.29e-05	0.000132	CcSEcCtD
Arformoterol—Gastrointestinal pain—Epirubicin—prostate cancer	2.27e-05	0.000131	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—prostate cancer	2.26e-05	0.000131	CcSEcCtD
Arformoterol—Vomiting—Prednisone—prostate cancer	2.26e-05	0.000131	CcSEcCtD
Arformoterol—Rash—Prednisone—prostate cancer	2.24e-05	0.00013	CcSEcCtD
Arformoterol—Dermatitis—Prednisone—prostate cancer	2.24e-05	0.00013	CcSEcCtD
Arformoterol—Headache—Prednisone—prostate cancer	2.23e-05	0.000129	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.22e-05	0.000128	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—prostate cancer	2.22e-05	0.000128	CcSEcCtD
Arformoterol—Urticaria—Epirubicin—prostate cancer	2.21e-05	0.000128	CcSEcCtD
Arformoterol—Pain—Doxorubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Arformoterol—Abdominal pain—Epirubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Arformoterol—Body temperature increased—Epirubicin—prostate cancer	2.2e-05	0.000127	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—prostate cancer	2.12e-05	0.000123	CcSEcCtD
Arformoterol—Nausea—Prednisone—prostate cancer	2.11e-05	0.000122	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—prostate cancer	2.1e-05	0.000122	CcSEcCtD
Arformoterol—Hypersensitivity—Epirubicin—prostate cancer	2.05e-05	0.000118	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—prostate cancer	2.04e-05	0.000118	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—prostate cancer	2.03e-05	0.000118	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—prostate cancer	2.03e-05	0.000118	CcSEcCtD
Arformoterol—Asthenia—Epirubicin—prostate cancer	1.99e-05	0.000115	CcSEcCtD
Arformoterol—Pruritus—Epirubicin—prostate cancer	1.97e-05	0.000114	CcSEcCtD
Arformoterol—Diarrhoea—Epirubicin—prostate cancer	1.9e-05	0.00011	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—prostate cancer	1.89e-05	0.00011	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—prostate cancer	1.84e-05	0.000107	CcSEcCtD
Arformoterol—Dizziness—Epirubicin—prostate cancer	1.84e-05	0.000106	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—prostate cancer	1.82e-05	0.000105	CcSEcCtD
Arformoterol—Vomiting—Epirubicin—prostate cancer	1.77e-05	0.000102	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—prostate cancer	1.76e-05	0.000102	CcSEcCtD
Arformoterol—Rash—Epirubicin—prostate cancer	1.75e-05	0.000101	CcSEcCtD
Arformoterol—Dermatitis—Epirubicin—prostate cancer	1.75e-05	0.000101	CcSEcCtD
Arformoterol—Headache—Epirubicin—prostate cancer	1.74e-05	0.000101	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—prostate cancer	1.7e-05	9.84e-05	CcSEcCtD
Arformoterol—Nausea—Epirubicin—prostate cancer	1.65e-05	9.55e-05	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—prostate cancer	1.63e-05	9.46e-05	CcSEcCtD
Arformoterol—Rash—Doxorubicin—prostate cancer	1.62e-05	9.38e-05	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—prostate cancer	1.62e-05	9.37e-05	CcSEcCtD
Arformoterol—Headache—Doxorubicin—prostate cancer	1.61e-05	9.32e-05	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—prostate cancer	1.53e-05	8.84e-05	CcSEcCtD
Arformoterol—ADRB2—Signaling Pathways—ITGB3—prostate cancer	5.03e-06	6.32e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—prostate cancer	5.02e-06	6.31e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—MTHFR—prostate cancer	5.01e-06	6.29e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ACHE—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB3—prostate cancer	4.99e-06	6.27e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGFR2—prostate cancer	4.98e-06	6.26e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—prostate cancer	4.95e-06	6.21e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ACHE—prostate cancer	4.95e-06	6.21e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2A6—prostate cancer	4.93e-06	6.2e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PPARA—prostate cancer	4.92e-06	6.17e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—prostate cancer	4.91e-06	6.17e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOA2—prostate cancer	4.9e-06	6.15e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2A6—prostate cancer	4.89e-06	6.14e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB3—prostate cancer	4.88e-06	6.13e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGFR2—prostate cancer	4.87e-06	6.12e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	4.87e-06	6.12e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—prostate cancer	4.8e-06	6.03e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKR1C3—prostate cancer	4.8e-06	6.03e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TERT—prostate cancer	4.78e-06	6.01e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PRKACB—prostate cancer	4.77e-06	5.99e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKR1C3—prostate cancer	4.76e-06	5.97e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PRKACB—prostate cancer	4.73e-06	5.94e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP17A1—prostate cancer	4.72e-06	5.93e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—prostate cancer	4.7e-06	5.9e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP17A1—prostate cancer	4.68e-06	5.88e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TERT—prostate cancer	4.68e-06	5.87e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC5A5—prostate cancer	4.67e-06	5.86e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CAV1—prostate cancer	4.62e-06	5.8e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	4.62e-06	5.8e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HIF1A—prostate cancer	4.57e-06	5.74e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP2E1—prostate cancer	4.56e-06	5.73e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NQO1—prostate cancer	4.51e-06	5.66e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA2—prostate cancer	4.5e-06	5.65e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HIF1A—prostate cancer	4.47e-06	5.62e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LEP—prostate cancer	4.47e-06	5.61e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA2—prostate cancer	4.46e-06	5.6e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TH—prostate cancer	4.44e-06	5.58e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CAV1—prostate cancer	4.42e-06	5.56e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.42e-06	5.55e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP3A4—prostate cancer	4.4e-06	5.52e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	4.38e-06	5.49e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—prostate cancer	4.37e-06	5.49e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LEP—prostate cancer	4.37e-06	5.48e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CAV1—prostate cancer	4.33e-06	5.43e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1B1—prostate cancer	4.32e-06	5.43e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC5A5—prostate cancer	4.3e-06	5.39e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—prostate cancer	4.28e-06	5.37e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ESR1—prostate cancer	4.26e-06	5.35e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC5A5—prostate cancer	4.26e-06	5.35e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CG—prostate cancer	4.21e-06	5.29e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP2E1—prostate cancer	4.2e-06	5.27e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GGT1—prostate cancer	4.19e-06	5.26e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ESR1—prostate cancer	4.17e-06	5.24e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BAD—prostate cancer	4.16e-06	5.22e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP2E1—prostate cancer	4.16e-06	5.22e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NQO1—prostate cancer	4.15e-06	5.21e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NCOA1—prostate cancer	4.12e-06	5.18e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NQO1—prostate cancer	4.11e-06	5.16e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TH—prostate cancer	4.09e-06	5.13e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BAD—prostate cancer	4.07e-06	5.11e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP19A1—prostate cancer	4.07e-06	5.1e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TH—prostate cancer	4.05e-06	5.09e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP3A4—prostate cancer	4.05e-06	5.08e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CG—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	4.03e-06	5.06e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP3A4—prostate cancer	4.01e-06	5.04e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	3.99e-06	5.01e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—INS—prostate cancer	3.99e-06	5e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGF—prostate cancer	3.98e-06	5e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IRS1—prostate cancer	3.98e-06	5e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1B1—prostate cancer	3.98e-06	4.99e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1B1—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CG—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—prostate cancer	3.94e-06	4.95e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—RXRA—prostate cancer	3.92e-06	4.93e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CREBBP—prostate cancer	3.9e-06	4.9e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGF—prostate cancer	3.9e-06	4.89e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IRS1—prostate cancer	3.9e-06	4.89e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GSK3B—prostate cancer	3.87e-06	4.86e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GGT1—prostate cancer	3.85e-06	4.84e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GGT1—prostate cancer	3.82e-06	4.79e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.82e-06	4.79e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—INS—prostate cancer	3.81e-06	4.79e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NCOA1—prostate cancer	3.79e-06	4.76e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GSK3B—prostate cancer	3.78e-06	4.75e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—COMT—prostate cancer	3.78e-06	4.75e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—prostate cancer	3.76e-06	4.72e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NCOA1—prostate cancer	3.76e-06	4.72e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP19A1—prostate cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CREBBP—prostate cancer	3.74e-06	4.69e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—INS—prostate cancer	3.73e-06	4.69e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP19A1—prostate cancer	3.71e-06	4.65e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ITPR1—prostate cancer	3.7e-06	4.65e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CD—prostate cancer	3.7e-06	4.65e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1—prostate cancer	3.69e-06	4.63e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—prostate cancer	3.67e-06	4.61e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CREBBP—prostate cancer	3.65e-06	4.59e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.64e-06	4.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1—prostate cancer	3.61e-06	4.53e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—RXRA—prostate cancer	3.61e-06	4.53e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—prostate cancer	3.59e-06	4.51e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—RXRA—prostate cancer	3.58e-06	4.49e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAP2K1—prostate cancer	3.57e-06	4.48e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CD—prostate cancer	3.54e-06	4.45e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—prostate cancer	3.51e-06	4.41e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SERPINE1—prostate cancer	3.5e-06	4.4e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—TYMS—prostate cancer	3.5e-06	4.39e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NOS3—prostate cancer	3.49e-06	4.39e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAP2K1—prostate cancer	3.49e-06	4.38e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	3.48e-06	4.37e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—COMT—prostate cancer	3.48e-06	4.37e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—prostate cancer	3.47e-06	4.35e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CD—prostate cancer	3.47e-06	4.35e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—prostate cancer	3.46e-06	4.34e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—prostate cancer	3.46e-06	4.34e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—COMT—prostate cancer	3.45e-06	4.33e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—prostate cancer	3.43e-06	4.31e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—prostate cancer	3.43e-06	4.31e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SERPINE1—prostate cancer	3.43e-06	4.3e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ITPR1—prostate cancer	3.4e-06	4.27e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—LPL—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FGF2—prostate cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ITPR1—prostate cancer	3.37e-06	4.24e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOS3—prostate cancer	3.35e-06	4.2e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	3.32e-06	4.17e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FGF2—prostate cancer	3.32e-06	4.17e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—prostate cancer	3.28e-06	4.11e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOS3—prostate cancer	3.27e-06	4.11e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JAK2—prostate cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ERCC2—prostate cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CB—prostate cancer	3.23e-06	4.05e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—TYMS—prostate cancer	3.22e-06	4.04e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—prostate cancer	3.2e-06	4.01e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—TYMS—prostate cancer	3.19e-06	4e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—prostate cancer	3.19e-06	4e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JAK2—prostate cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—prostate cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MDM2—prostate cancer	3.17e-06	3.99e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—prostate cancer	3.15e-06	3.96e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—prostate cancer	3.13e-06	3.93e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—LPL—prostate cancer	3.12e-06	3.92e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—prostate cancer	3.12e-06	3.91e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MDM2—prostate cancer	3.1e-06	3.9e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—LPL—prostate cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CB—prostate cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—prostate cancer	3.06e-06	3.84e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—MTHFR—prostate cancer	3.05e-06	3.84e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CB—prostate cancer	3.02e-06	3.79e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—prostate cancer	3.01e-06	3.78e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPARA—prostate cancer	3e-06	3.76e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ERCC2—prostate cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—prostate cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—prostate cancer	2.97e-06	3.73e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ERCC2—prostate cancer	2.96e-06	3.72e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—prostate cancer	2.9e-06	3.64e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—prostate cancer	2.9e-06	3.64e-05	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—AKT1—prostate cancer	2.87e-06	3.6e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP3—prostate cancer	2.84e-06	3.57e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—prostate cancer	2.84e-06	3.56e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—prostate cancer	2.83e-06	3.56e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—prostate cancer	2.82e-06	3.54e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CAV1—prostate cancer	2.82e-06	3.54e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—MTHFR—prostate cancer	2.81e-06	3.53e-05	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—AKT1—prostate cancer	2.8e-06	3.52e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—prostate cancer	2.79e-06	3.5e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—MTHFR—prostate cancer	2.79e-06	3.5e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP3—prostate cancer	2.78e-06	3.49e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—prostate cancer	2.77e-06	3.48e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—prostate cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—prostate cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPARA—prostate cancer	2.76e-06	3.46e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNB1—prostate cancer	2.74e-06	3.44e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPARA—prostate cancer	2.73e-06	3.43e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—prostate cancer	2.7e-06	3.4e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.69e-06	3.38e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—prostate cancer	2.68e-06	3.37e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNB1—prostate cancer	2.68e-06	3.36e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1A—prostate cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—prostate cancer	2.67e-06	3.35e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—EP300—prostate cancer	2.66e-06	3.34e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—prostate cancer	2.63e-06	3.3e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1A—prostate cancer	2.62e-06	3.28e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—prostate cancer	2.61e-06	3.28e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—AKT1—prostate cancer	2.6e-06	3.27e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CAV1—prostate cancer	2.59e-06	3.25e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CAV1—prostate cancer	2.57e-06	3.23e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CG—prostate cancer	2.57e-06	3.22e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—AKT1—prostate cancer	2.55e-06	3.2e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EP300—prostate cancer	2.54e-06	3.2e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EP300—prostate cancer	2.49e-06	3.13e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SRC—prostate cancer	2.47e-06	3.11e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	2.45e-06	3.08e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—INS—prostate cancer	2.43e-06	3.05e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SRC—prostate cancer	2.42e-06	3.04e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—prostate cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—STAT3—prostate cancer	2.39e-06	3e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CREBBP—prostate cancer	2.38e-06	2.99e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CG—prostate cancer	2.36e-06	2.96e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—prostate cancer	2.36e-06	2.96e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CG—prostate cancer	2.34e-06	2.94e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—STAT3—prostate cancer	2.33e-06	2.93e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CD—prostate cancer	2.26e-06	2.83e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—INS—prostate cancer	2.23e-06	2.81e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—prostate cancer	2.22e-06	2.78e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—INS—prostate cancer	2.22e-06	2.78e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFB1—prostate cancer	2.21e-06	2.78e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CREBBP—prostate cancer	2.19e-06	2.75e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CREBBP—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—prostate cancer	2.17e-06	2.72e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFB1—prostate cancer	2.16e-06	2.72e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NOS3—prostate cancer	2.13e-06	2.68e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—prostate cancer	2.12e-06	2.66e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CD—prostate cancer	2.08e-06	2.61e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CD—prostate cancer	2.06e-06	2.58e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—prostate cancer	2.05e-06	2.57e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—prostate cancer	2e-06	2.52e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CB—prostate cancer	1.97e-06	2.47e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—prostate cancer	1.97e-06	2.47e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NOS3—prostate cancer	1.96e-06	2.46e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—prostate cancer	1.95e-06	2.45e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NOS3—prostate cancer	1.94e-06	2.44e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—prostate cancer	1.88e-06	2.36e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—prostate cancer	1.84e-06	2.31e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—prostate cancer	1.82e-06	2.29e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.81e-06	2.27e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CB—prostate cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—prostate cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—prostate cancer	1.78e-06	2.24e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—prostate cancer	1.78e-06	2.23e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—prostate cancer	1.7e-06	2.13e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—prostate cancer	1.67e-06	2.09e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—prostate cancer	1.63e-06	2.05e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—EP300—prostate cancer	1.62e-06	2.04e-05	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—AKT1—prostate cancer	1.61e-06	2.02e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—prostate cancer	1.56e-06	1.96e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—prostate cancer	1.55e-06	1.95e-05	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKT1—prostate cancer	1.54e-06	1.93e-05	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKT1—prostate cancer	1.5e-06	1.89e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—EP300—prostate cancer	1.49e-06	1.87e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—EP300—prostate cancer	1.48e-06	1.86e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—prostate cancer	1.2e-06	1.51e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—prostate cancer	1.1e-06	1.38e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—prostate cancer	1.09e-06	1.37e-05	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—AKT1—prostate cancer	9.79e-07	1.23e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—AKT1—prostate cancer	9.01e-07	1.13e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—AKT1—prostate cancer	8.93e-07	1.12e-05	CbGpPWpGaD
